Nitronazine is under clinical development by Guangzhou Magpie Pharmaceutical and currently in Phase II for Amyotrophic Lateral Sclerosis.
Digital health startup Ro’s CEO talks GLP-1 drug pricing, shortages and compounded shots
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) The fight to dominate the market for